Research Resources

FRAXA’s primary mission is to speed up progress towards effective treatments and a cure for Fragile X. As “bottlenecks” are identified we will try to facilitate solutions and add resources for university and pharma researchers worldwide, so please contact us for additional scientific resource requests.

Models and Reagents

Mutant Mouse Models
Mutant Mouse Models

Knockout Mice are available from Jackson Laboratory.

FMR1 Knockout Rats
FMR1 Knockout Rats

This model contains a deletion of the Fragile X mental retardation 1 gene (Fmr1). Mutations in Fmr1 result in Fragile X syndrome, the leading monogenic cause of autism, making this rat useful for the study of both Fragile X syndrome and autism.

Sold by Envigo (based in U.S.) and also by AnimaLab (based in Poland).

Human Stem Cells
Human Stem Cells

The National Human Neural Stem Cell Resource (SCR) provides to the research community neural stem cells harvested from the post-natal, post-mortem, human brain. Dr. Philip Schwartz directs this resource at the Children’s Hospital of Orange County (CHOC) Research Institute.

Human cortical neural stem cells that carry the Fragile X mutation are available for distribution to interested researchers. These cells are grown as neurospheres and are mainly neural progenitor cells. They can be differentiated into neurons and astrocytes that lack FMRP with long-term culturing. For more information about these cells please refer to Svendsen et al., J Neuroscience Methods 85:141-163 (1998), and contact Dr. Anita Bhattacharyya at the University of Wisconsin-Madison Waisman Center.

FMRP Antibodies
FMRP Antibodies

Several antibodies to mouse and drosophila fmrp are available at cost from the University of Iowa Developmental Studies Hybridoma Bank (DSHB). This is an NIH-funded facility.

Human Brain Tissue
Human Brain Tissue

Announcements

Job Listing: Neurodevelopmental Disorders Postdoctoral Research Fellow

The Kansas Center for Autism Research and Training (K-CART) and Life Span Institute at the University of Kansas currently are seeking one postdoctoral fellow interested in advancing their research skills and progressing towards a career as an independent, externally funded investigator studying autism spectrum (ASD) or related neurodevelopmental disorders (e.g., Fragile X syndrome).
Read more

Fragile X Syndrome Drug Validation Initiative (FRAXA-DVI)

The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing of potential new Fragile X treatments. FRAXA has funded FRAXA-DVI for $50,000 or more per year since 2012.
Read more
Resources for scientists

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Copy link